The goal of this study is the analysis of the impact of type 2 diabetes mellitus and anti-diabetic treatment on the occurrence of specific cancer entities.
The project is based on enrollment data of a Disease Management Program for type 2 diabetes (DMP-DM2) implemented by the statutory health insurance fund AOKNordWest in 2003. First-ever invasive cancer cases are identified by linking DMP-DM2 data with the epidemiological cancer registry of the state of North-Rhine-Westphalia. Data for pharmacy-claimed anti-diabetic medications during the study period are provided by AOK. The impact of different antihyperglycaemic treatments, including human insulin, insulin glargine and metformin is assessed taking time- and dose-dependent relationships into account.
|Contact person:||Andrea Fuhs|
|Coordination:||Klaus Berger, Andrea Fuhs|
|Funding:||German Cancer Aid (Deutsche Krebshilfe)|
|Collaborators:||Epidemiological cancer registry NRW, AOK NordWest|
|State:||Start of the project in 2011; Funding period 01.10.2012 – 30.09.2014; data analysis|